Explore our multimedia assets, recordings, publications, and much more to add to your knowledge of multiple myeloma treatment options and related topics.
Download the MMRF Patient Toolkit—available in English and Spanish—or order a copy through the mail.
Thank you to our sponsors: Abbvie, CURE, Genentech, Karyopharm, Pfizer, Regeneron, and Sanofi.
Newly Diagnosed Multiple Myeloma
This booklet describes some of the first steps you will want to take after receiving a myeloma diagnosis, as well as what you can expect from your treatment team.
Multiple Myeloma Learn Your Labs
This booklet describes these tests and what they mean for you and your health care team.
Multiple Myeloma Treatment Overview
This booklet describes current therapies for myeloma as well as emerging treatment options that are being tested in clinical trials.
Multiple Myeloma Disease Overview
This booklet is designed to help patients with multiple myeloma - and their friends, families, and caregivers - better understand this disease: what myeloma is and how it develops within the body.
Managing My Myeloma Resource Brochure
Find resources that will help you through your journey with multiple myeloma.
Myeloma Precursor Conditions
Patients with multiple myeloma typically have a preceding phase of disease in which there are changes in the bone marrow but no symptoms or organ damage.
Immunotherapy
The use of a patient’s immune system to fight cancer—cancer immunotherapy—is an exciting area of multiple myeloma research.
Autologous Stem Cell Transplantation
Autologous Stem Cell Transplantation (ASCT) remains the standard of care for newly diagnosed, eligible patients.
Note: The MMRF cannot ship to addresses outside the USA.
Central to MMRF’s mission is providing educational content no matter where patients and caregivers may be in the multiple myeloma diagnostic and treatment journey. Discover our full range of information options.
Our goal is to share resources and insights on clinical progress and precise treatments for all patients and their caregivers.
To deliver the highest possible level of patient care, the MMRF supports continuous learning for healthcare providers. To keep pace with evolving evidence-based clinical innovations, technologies, and best practices, MMRF provides access to both CME-accredited and non-accredited education and activities.
Prevention and Management of Bispecific Antibody–Associated Adverse Events in Multiple Myeloma (non-accredited activity)
This is a non-accredited activity.
For health care providers looking to incorporate bispecific antibody therapy into their practices, familiarity with strategies for preventing and managing potentially life-threatening adverse events is essential.
Expires: May 1, 2025
Unmasking Multiple Myeloma and Its Precursor Conditions in Primary Care (CME-accredited activity)
AMA PRA Category 1 Credit™
ABIM MOC Point
Primary care providers are in the best position to identify patients with MM or its precursor conditions, but diagnosing these conditions is challenging.
Expires: March 15, 2025
Addressing Key Questions About BCMA-Targeted Therapy for Relapsed/Refractory Multiple Myeloma (CME-accredited activity)
AMA PRA Category 1 Credit™
Experts provide evidence-based responses to challenging questions on incorporating new and emerging BCMA-targeted therapies that achieve durable remission for RRMM patients.
Expires: March 11, 2025
Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma
This webcast features evidence-based presentations along with patient cases designed to address the nuances of T cell—activating therapy use, identification of patients that are the best candidates for these approaches, and options for patients who may not be candidates for this therapy.
What’s My (Next) Line? Treating Relapsed/Refractory Multiple Myeloma When Three Prior Treatment Lines Fail
This activity has been developed to present and discuss current recommended strategies for individualizing treatment plans for patients with RRMM by incorporating the most up-to-date clinical evidence on sequencing small molecule–based therapies and BCMA-targeted therapies that achieve durable remission while minimizing toxicity.
Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting (Oncology)
Applying the Latest Clinical Data in Multiple Myeloma Patient Care in the Community Setting (Internal Medicine)